Scinai Immunotherapeutics Ltd.
SCNI
$0.51
-$0.03-5.07%
NASDAQ
| 12/31/2025 | 06/30/2025 | 12/31/2024 | 09/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 30.58% | 36.09% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.58% | 36.09% | -- | -- | -- |
| Cost of Revenue | 157.37% | 128.01% | -- | -- | -- |
| Gross Profit | -313.77% | -287.20% | -- | -- | -- |
| SG&A Expenses | -16.67% | 21.00% | -37.01% | 0.10% | -17.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.58% | -1.86% | 35.44% | -2.73% | 21.84% |
| Operating Income | 16.50% | 7.18% | -24.14% | 2.73% | -21.84% |
| Income Before Tax | 6.43% | 10.98% | 4.29% | -165.03% | -42.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 6.43% | 10.98% | 4.29% | -165.03% | -42.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.43% | 10.98% | 4.29% | -165.03% | -42.02% |
| EBIT | 16.50% | 7.18% | -24.14% | 2.73% | -21.84% |
| EBITDA | 13.21% | 0.10% | -1.44% | 2.93% | -22.85% |
| EPS Basic | 88.08% | 64.33% | 26.70% | -127.07% | 18.34% |
| Normalized Basic EPS | 95.07% | 64.33% | -77.23% | -- | 18.34% |
| EPS Diluted | 88.08% | 64.33% | 45.51% | -127.07% | 9.73% |
| Normalized Diluted EPS | 95.07% | 64.33% | -77.23% | -- | 18.34% |
| Average Basic Shares Outstanding | 149.11% | 149.56% | 311.38% | 140.12% | 73.90% |
| Average Diluted Shares Outstanding | 133.33% | 200.00% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |